

Dated: \_\_\_\_\_

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Not Yet Assigned

{W:\09859\0202758us0\00462447.DOC 00000000000000000000000000000000}

defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: June 28, 2005

Respectfully submitted,

By

Chris T. Mizumoto

Registration No.: 42,899

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

Substitute for form 1449A/B/PTO  <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 0;">(Use as many sheets as necessary)</p>				<b>Complete if Known</b>	
Application Number	10/531,099				
Filing Date	April 7, 2005				
First Named Inventor	Yukimasa Shiotsu				
Art Unit	N/A				
Examiner Name	Not Yet Assigned				
Attorney Docket Number	09859/0202758-USO				

Sheet	1	of	2	
-------	---	----	---	--

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/K.B./	AA	US-5,616,574	04-01-1997	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE		
	AB	US-5,830,886	11-03-1998	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE		
	AC	US-5,567,831	10-22-1996	DUGUESNE UNIVERSITY OF THE HOLY GHOST		
	AD	US-6,011,024	01-04-2000	IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY & MEDICINE		
	AE	US-6,087,347	07-11-2000	TEIKOKU HORMONE MFG. CO., LTD.		
V	AF	US-6,762,205	07-13-2004	TEIKOKU HORMONE MFG. CO., LTD.		
/K.B./	AG	US-20040254241-A1	12-16-2004	INO, Yoji et al.		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> -Number <sup>3</sup> -Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/K.B./	BA	WO-98/32763-A1	07-30-1998	SRI INTERNATIONAL		
	BB	WO-01/04086-A1	01-18-2001	KINGSTON UNIVERSITY		
	BC	WO-93/05064-A1	03-18-1993	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE		
	BD	WO-97/30041-A1	08-21-1997	IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE		
	BE	WO-99/52890-A1	10-21-1999	NOVARTIS AG		
	BF	WO-01/36398-A1	05-25-2001	NOVARTIS AG		
	BG	WO-99/33858-A2	07-08-1999	SRI INTERNATIONAL		
	BH	WO-00/43408-A2	07-27-2000	DUGUESNE UNIVERSITY OF THE HOLY GHOST		
V	BI	WO-02/064142-A1	08-22-2002	JANSSEN PHARMACEUTICA N.V.		
/K.B./	BJ	EP-1 364 643-A1	11-26-2003	KYOWA HAKKO KOGYO CO., LTD.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 806. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

/Kristie Brooks/	Date Considered	03/23/2009
------------------	--------------------	------------

Substitute for form 1449A/B/PTO  <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;">(Use as many sheets as necessary)</p>		<b>Complete if Known</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/531,099</td> </tr> <tr> <td>Filing Date</td> <td>April 7, 2005</td> </tr> <tr> <td>First Named Inventor</td> <td>Yukimasa Shiotsu</td> </tr> <tr> <td>Art Unit</td> <td>N/A</td> </tr> <tr> <td>Examiner Name</td> <td>Not Yet Assigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>09859/0202758-USO</td> </tr> </table>		Application Number	10/531,099	Filing Date	April 7, 2005	First Named Inventor	Yukimasa Shiotsu	Art Unit	N/A	Examiner Name	Not Yet Assigned	Attorney Docket Number	09859/0202758-USO
Application Number	10/531,099														
Filing Date	April 7, 2005														
First Named Inventor	Yukimasa Shiotsu														
Art Unit	N/A														
Examiner Name	Not Yet Assigned														
Attorney Docket Number	09859/0202758-USO														
Sheet	2	of	2												

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
/K.B./	CA	"In Vivo Inhibition of Oestrone Sulphatase and Dehydroepiandrosterone Sulphatase by Oestrone-3-O-Sulphamate", A. Purohit et al, International Journal of Cancer, Vol. 63, pp. 106-111 (1995)		
	CB	"In Vivo Activity of 4-Methylcoumarin-7-O-Sulfamate, a Nonsteroidal, Nonestrogenic Steroid Sulfatase Inhibitor", Atul Purohit et al, Cancer Research, Vol. 56, pp. 4950-4955 (November 1, 1996)		
	CC	"Steroid Sulfatase Inhibitors", Donald Poirier et al, Expert Opinion on Therapeutic Patents, Vol. 9, pp. 1063-1099 (1999)		
	CD	"Inhibition of Estrone Sulfatase and Proliferation of Human Breast Cancer Cells by Nonsteroidal (p-O-Sulfamoyl)-N-alkanoyl Tyramines", Kyle W. Selcer et al, Cancer Research, Vol. 57, pp. 702-707 (1997)		
	CE	"Synthesis and Sulfatase Inhibitory Activities of Non-steroidal Estrone Sulfatase Inhibitors", Pui-Kai Li et al, The Journal of Steroid Biochemistry and Molecular Biology, Vol. 59, pp. 41-48 (1996)		
	CF	"Development of (p-O-sulfamoyl)-N-alkanoyl-phenylalkyl amines as non-steroidal estrone sulfatase inhibitors", Aparna Kolli et al, The Journal of Steroid Biochemistry and Molecular Biology, Vol. 68, pp. 31-40 (1999)		
	CG	"Recent Advances in the Development of Steroid Sulphatase Inhibitors", A. Purohit et al, The Journal of Steroid Biochemistry and Molecular Biology, Vol. 69, pp. 227-238 (1999)		
	CH	"Inhibition of Estrone Sulfatase Activity by Estrone-3-methylthiophosphonate: A Potential Therapeutic Agent in Breast Cancer", L. Duncan et al, Cancer Research, Vol. 53, pp. 298-303 (January 15, 1993)		
/K.B./	CI	"Phosphonates and Thiophosphonates as Sulfate Surrogates: Synthesis of Estrone 3-methylthiophosphonate, a Potent Inhibitor of Estrone Sulfatase", Nicola M. Howarth et al, Bioorganic and Medical Chemistry Letters, Vol. 3, pp. 313-318 (1993)		
	CJ	"Development of Potent Non-estrogenic Estrone Sulfatase Inhibitors", Pui-Kai Li et al, Steroids, Vol. 63, pp. 425-432 (1998)		

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

/Kristie Brooks/	Date Considered	03/23/2009
------------------	-----------------	------------